Open AccessP556: CHANGES IN HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY‐DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB + AZACITIDINE OR PLACEBO + AZACITIDINE
Author(s) -
Schuh A.,
Botton S.,
Recher C.,
Vives Polo S.,
Zarzycka E.,
Wang J.,
Bertani G.,
Heuser M.,
Calado R.,
Yeh S.P.,
Hui J.,
Pandya S.,
Gianolio D.,
Chamberlain C.,
Dohner H.,
Montesinos P.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845112.68080.6b
Subject(s) - placebo , medicine , azacitidine , quality of life (healthcare) , clinical endpoint , myeloid leukemia , clinical trial , alternative medicine , biochemistry , gene expression , pathology , dna methylation , gene , chemistry , nursing